Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 901 to 915 of 7680 results

  1. Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia (TA218)

    Evidence-based recommendations on azacitidine (Vidaza) for treating myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia in adults.

  2. Golimumab for the treatment of psoriatic arthritis (TA220)

    Evidence-based recommendations on golimumab (Simponi) for treating psoriatic arthritis in adults.

  3. Fulvestrant for the treatment of locally advanced or metastatic breast cancer (TA239)

    Evidence-based recommendations on fulvestrant (Faslodex), for treating locally advanced or metastatic breast cancer in adults.

  4. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243)

    Evidence-based recommendations on rituximab for treating follicular lymphoma in adults.

  5. Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (TA245)

    Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism after total hip or knee replacement in adults.

  6. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine (TA260)

    Evidence-based recommendations on botulinum toxin type A (Botox) for preventing headaches in adults with chronic migraine.

  7. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)

    Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis and preventing a pulmonary embolism or another deep vein thrombosis in adults.

  8. Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer (TA263)

    Evidence-based recommendations on bevacizumab (Avastin), with capecitabine, for treating metastatic breast cancer in adults.

  9. Holoclar for treating limbal stem cell deficiency after eye burns (TA467)

    Evidence-based recommendations on Holoclar (a layer of cells grown from cells taken from your own eye) for treating limbal stem cell deficiency in adults with eye burns.

  10. Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA47)

    Evidence-based recommendations on glycoprotein IIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) for treating acute coronary syndromes in adults.

  11. Alitretinoin for the treatment of severe chronic hand eczema (TA177)

    Evidence-based recommendations on alitretinoin (Toctino) for treating severe chronic hand eczema in adults.

  12. Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)

    Evidence-based recommendations on bevacizumab (Avastin), sorafenib (Nexavar), sunitinib (Sutent) and temsirolimus (Torisel) for treating advanced or metastatic renal cell carcinoma in adults.

  13. Pemetrexed for the first-line treatment of non-small-cell lung cancer (TA181)

    Evidence-based recommendations on pemetrexed for untreated non-small-cell lung cancer in adults.

  14. Topotecan for the treatment of recurrent and stage IVB cervical cancer (TA183)

    Evidence-based recommendations on topotecan for treating recurrent and stage IVB cervical cancer in adults.